6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-carboxylic acid | 14378-56-4

• 分子结构分类: 有机化合物 - 苯类化合物
• 英文名称: 6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-carboxylic acid
• CAS: 14378-56-4
• 化学式: C₁₂H₁₄O₂
• mdl: MFCD02179126
• 分子量: 190.242
• InChiKey: IWWVDVJJFIJZQE-UHFFFAOYSA-N

物化性质

• 沸点：
  356.2±21.0 °C(Predicted)
• 密度：
  1.144±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-carboxylic acid 生成 1-Methylbenzosuberen-1-carbonsaeuremethylester
  参考文献：
  名称：

  Ring size effects in the neophyl rearrangement. VIII. Synthesis and solvolysis of 1-methyl-2,3-benzocycloalkenylcarbinyl tosylates

  摘要：

  DOI：

  10.1021/jo00971a003
• 作为产物：
  描述：

  5-(2-chlorophenyl)pentan-1-ol 在 吡啶 、 氯化亚砜 、 氨 作用下， 以 乙醇 为溶剂， 生成 6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-carboxylic acid
  参考文献：
  名称：

  Homocyclic Ring Closures via Benzyne Intermediates. A New Synthesis of 1-Substituted Benzocyclobutenes¹

  摘要：

  DOI：

  10.1021/jo01058a019

文献信息

• [EN] AMINOTRIAZOLE IMMUNOMODULATORS FOR TREATING AUTOIMMUNE DISEASES<br/>[FR] IMMUNOMODULATEURS D'AMINOTRIAZOLE POUR TRAITER DES MALADIES AUTO-IMMUNES
  申请人：UNIV ROCKEFELLER

  公开号：WO2017123518A1

  公开（公告）日：2017-07-20

  1-Acyl-3-(heteroaryl)-1H-1,2,4-triazol-5-amines of formula (I) are disclosed. These compounds inhibit Coagulation Factor XIIa in the presence of thrombin and other coagulation factors. They are useful to treat autoimmune diseases.

  1-酰基-3-(杂芳基)-1H-1,2,4-三唑-5-胺的公式(I)化合物被公开。这些化合物在存在凝血酶和其他凝血因子时抑制凝血因子XIIa。它们可用于治疗自身免疫疾病。
• Fused bicyclic carboxamide derivatives and methods of their use
  申请人：Dolle E. Roland

  公开号：US20050054630A1

  公开（公告）日：2005-03-10

  Fused bicyclic carboxamide derivatives are disclosed. Pharmaceutical compositions containing the compounds and methods for their use are also disclosed.

  揭示了融合的双环羧酰胺衍生物。还公开了含有这些化合物的药物组合物以及它们的使用方法。
• Synthesis of 3,3-Disubstituted Oxindoles by Palladium-Catalyzed Asymmetric Intramolecular α-Arylation of Amides: Reaction Development and Mechanistic Studies
  作者：Dmitry Katayev、Yi-Xia Jia、Akhilesh K. Sharma、Dipshikha Banerjee、Céline Besnard、Raghavan B. Sunoj、E. Peter Kündig

  DOI：10.1002/chem.201301572

  日期：2013.9.2

  their performance is compared. One of them, L8, containing a tBu and a 1‐naphthyl group at the stereogenic centre, proved superior and was very efficient in the asymmetric synthesis of fifteen new spiro‐oxindoles and three azaspiro‐oxindoles often in high yields (up to 99 %) and enantioselectivities (up to 97 % ee; ee=enantiomeric excess). Three palladacycle intermediates resulting from the oxidative addition

  掺有手性N-杂环卡宾（NHC）配体的钯配合物催化酰胺的不对称分子内α-芳基化反应，生成3,3-二取代的羟吲哚。已经进行了全面的DFT研究，以深入了解这种转变的机制。氧化添加被证明是决定速率的，还原消除是对映选择性的决定。详细介绍了七个新的NHC配体的合成，并比较了它们的性能。其中之一，L8，在立体异构中心含有一个t Bu和一个1-萘基，被证明是优越的，并且在不对称合成15个新的螺-氧杂吲哚和3个氮杂-螺氧杂吲哚中通常非常高的收率（高达99） ％）和对映选择性（高达97％  ee; ee =对映体过量）。分离并氧化了[Pd（NHC）]到芳基卤化物键中形成的三种palladacycle中间体，并对其结构进行了表征（X射线）。使用这些中间体作为催化剂，表明烯烃添加剂在增加周转次数和频率中起着重要的作用。
• Novel amide derivatives and medicinal use thereof ugs
  申请人：——

  公开号：US20040138223A1

  公开（公告）日：2004-07-15

  The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action 1 wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

  本发明涉及一种式（1）的酰胺衍生物，具有C5a受体拮抗作用，其中每个符号如规范中所定义。上述酰胺衍生物及其光学活性形式和药学上可接受的盐被认为是治疗或预防因C5a引起的炎症引起的疾病或综合症的药物，如自身免疫性疾病，如风湿病，系统性红斑狼疮等，败血症，成人呼吸窘迫综合症，慢性阻塞性肺疾病，哮喘等过敏性疾病，动脉粥样硬化，心脏梗死，脑梗死，牛皮癣，老年痴呆症和严重器官损伤（如肺炎，肾炎，肝炎，胰腺炎等）由于缺血再灌注，创伤，烧伤，手术入侵等引起的白细胞激活。此外，它们对通过C5a受体侵入的细菌和病毒引起的传染病也有用作治疗或预防剂。
• Amide Derivatives as Kinase Inhibitors
  申请人：Defert Olivier Raynald

  公开号：US20090118283A1

  公开（公告）日：2009-05-07

  The present invention relates to new AGC kinase inhibitors, in particular to compounds of Formula (I) or (II) or a stereoisomer tautomer, racemic, metabolite, pro- or predrug, salt, hydrate, or solvate thereof, wherein Ar 1 , Ar 2 , R 1 , R 3 , p and n have the meaning defined in the claims In particular, the present invention relates to more specifically AGC kinases inhibitors, compositions, in particular pharmaceuticals, comprising such inhibitors, and to uses of such inhibitors in the treatment and prophylaxis of disease.

  本发明涉及新的AGC激酶抑制剂，特别是公式（I）或（II）的化合物或其立体异构体、互变异构体、外消旋体、代谢物、前药或前药、盐、水合物或溶剂化物，其中Ar1、Ar2、R1、R3、p和n在权利要求中定义。特别地，本发明涉及更具体的AGC激酶抑制剂、包含这种抑制剂的组合物，特别是药物，以及在治疗和预防疾病中使用这种抑制剂的用途。